Description de fonction

Université Libre de Bruxelles (ULB) Fellowship Program Open Fellowship position for a Nuclear Medicine Physician At Institut Jules Bordet (Brussels/Belgium)

Détails de la société

The Institut Jules Bordet (www.bordet.be), a university teaching hospital of the Université Libre de Bruxelles (U.L.B), is a comprehensive cancer center in Belgium, located in the heart of Brussels. Its services range from cancer screening to multidisciplinary cancer treatment and state-of-the art clinical and laboratory research, for which the Institute is renowned on both the national and international levels.

The aim of the Nuclear Medicine dpt is to bring the field of radiotheranostics to the forefront of modern oncology and make it available to cancer patients employing the highest standards of quality & care. We intend to develop innovative applications of radiotheranostics, translate them into the clinic and increase access to existing products for cancer patients.

During the last decade IJB performed significant R&D using the “radiotheranostic approach”:

    • 68Ga/177Lu-octreotate for neuroendocrine tumors
    • 99mTc-MAA/90Y-microspheres for radioembolization of liver tumors
    • 89Zr/90Y-rituximab for CD-20 positive lymphomas
    • 99mTc-MDP/223Radium (alpha emitter) for therapy of bone metastasis

    • 68Ga/177Lu-PSMA (under development) for therapy of prostate cancer

The Nuclear Medicine dpt. is equiped with 2 SPECT/CT, 1 PET/CT and three dedicated hospitalization rooms for patient isolation during radionuclide therapies. In 2018, 3000 SPECT/CT and 6000 PET/CT scans have been performed, together with 240 radionuclide therapies.

Fonction

This fellowship will be particularly focusing on the theranostic applications in uro-oncology using PSMA targeting radiotracers for diagnosis (Ga68 / F18-labeled) and therapy (Lu177-labeled). He will work in a multidisciplinary environment of nuclear medicine, oncology, urology, radiopharmacy and medical physics.

A fellowship at the ULB provides a unique experience for a nuclear medicine physician to become familiar with all aspects of the development and conduct of cancer clinical trials.

Fellowship activities include:

  1. Writing, discussing, and developing new study protocols on PSMA-imaging in urological cancer (phase I to III studies);
  2. Writing review and research articles, book chapters, and abstracts under the guidance of a senior oncologist and nuclear medicine physician with expertise in uro-oncology;
  3. Writing grant applications whenever required;
  4. Attending and presenting journal clubs;
  5. Interacting with other departments within the institution for related research activities;
  6. Attending oncology conferences, meetings and workshops;
  7. Participating to the relevant tumour board meetings.

Profil

To be eligible, candidates must:

  • Hold a degree in medicine and have recently completed, or are soon to complete, their specialization in Nuclear Medicine;
  • Be no older than 35 years;
  • Preferably have some clinical research and publication background;
  • Be fluent in English (French and/or Dutch are an asset);
  • Possess excellent communication skills and team spirit;
  • Be able to work within established deadlines;
  • Be able to work on different activities (multi-task);
  • Possess computer skills (Microsoft office);

Offre

Remuneration
The fellow will receive a monthly salary in agreement with the official ULB fellowship salary levels (ULB contract)

Please send us your curriculum vitae, recommendation letter and a motivation letter.

Application closing date: end of August 2019

Number of vacancies: 1

Start date: December: September-October 2019

Duration of fellowship: 1 to a maximum of 3 years (renewed on a yearly basis based on performance)

Note: All documents must be submitted in English. Incomplete submissions will not be considered.

  • Publiée le:jeu. 9 mai 2019
  • Lieu: Institut Jules Bordet
E-mail
Veuillez patienter durant le traitement de votre demande
Mail vers vos amis
Mail(s) envoyé avec succès
Une erreur c'est produite, veuillez contacter votre administrateur système
[fermer]